SHIRE PLC (NASDAQ:SHPG) Files An 8-K Other Events

SHIRE PLC (NASDAQ:SHPG) Files An 8-K Other Events
Item 8.01. Other Events

Story continues below

Shire plc has issued the press releases attached hereto as Exhibits 99.1, 99.2 and 99.3, which are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibits are filed herewith:

99.1 Press Release dated October 5, 2018
99.2 Press Release dated October 8, 2018
99.3 Press Release dated October 10, 2018


Shire plc Exhibit
EX-99.1 2 october52018-rule29xexhibi.htm EXHIBIT 99.1 Exhibit EXHIBIT 99.1NOT FOR RELEASE,…
To view the full exhibit click here


Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

An ad to help with our costs